Factors Influencing the Efficacy and Safety of Monoclonal Antibody Biologics in Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials
Lung · 2025
DOI: 10.1007/s00408-025-00795-6 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Lung, 2025. Verfasst von Yuxin Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Biological Products, Lung, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Themen: COPD
Abstract (Originalsprache)
BACKGROUND: Monoclonal antibody therapies targeting specific inflammatory pathways have shown potential in treating chronic obstructive pulmonary disease (COPD). However, the efficacy and safety of these treatments across different patient phenotypes remain uncertain. METHODS: This meta-analysis included 15 registered randomized controlled trials (RCTs) evaluating monoclonal antibodies targeting type 2 and non-type 2 inflammatory pathways in COPD. The primary outcomes assessed were rates of moderate to severe exacerbations, rates of severe exacerbations, lung function (pre- and post-bronchodilator FEV1), St. George's Respiratory Questionnaire (SGRQ) scores, and safety-related events. Subgroup analyses were performed based on inflammatory phenotype, exacerbation frequency, and smoking status. Meta-regression was used to examine the influence of covariates, such as baseline FEV1%pred and other demographic factors. RESULTS: Monoclonal antibody therapies significantly reduced the rates of moderate to severe exacerbations (RR 0.88, 95% CI 0.83-0.93) and severe exacerbations (RR 0.82, 95% CI 0.72-0.94). Subgroup analyses revealed more pronounced benefits in eosinophilic and frequent exacerbator phenotypes. Non-eosinophilic patients demonstrated a better response to IL-33-targeting therapies. Lung function and quality of life showed modest improvements across most therapies. Smoking status and baseline FEV1 were significant modifiers of treatment efficacy. No significant increase in serious adverse events was noted. CONCLUSIONS: Monoclonal antibody therapies, particularly those targeting type 2 inflammation, effectively reduce exacerbation rates in COPD, with greater benefits observed in patients with eosinophilic phenotypes and frequent exacerbations. Baseline lung function also influences treatment response. These findings underscore the importance of personalized, phenotype-driven treatment approaches and support the continued development of biologics for COPD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, No. 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, Chin…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., Luo, J., Huang, R., & Xiao, Y. (2025). Factors Influencing the Efficacy and Safety of Monoclonal Antibody Biologics in Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials. Lung. https://doi.org/10.1007/s00408-025-00795-6
Vancouver
Wang Y, Luo J, Huang R, Xiao Y. Factors Influencing the Efficacy and Safety of Monoclonal Antibody Biologics in Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials. Lung. 2025. doi:10.1007/s00408-025-00795-6
BibTeX
@article{Wang2025,
author = {Wang, Yuxin and Luo, Jinmei and Huang, Rong and Xiao, Yi},
title = {Factors Influencing the Efficacy and Safety of Monoclonal Antibody Biologics in Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials},
journal = {Lung},
year = {2025},
doi = {10.1007/s00408-025-00795-6}
}
EUVIMED